Group 1 - The stock of Yiming Oncology-B (01541) increased by over 12%, reaching HKD 12.72 with a trading volume of HKD 23.9 million [1] - Yiming Oncology has submitted two EOP2 communication requests for its self-developed VEGF×PD-L1 bispecific antibody IMM2510 to the National Medical Products Administration for Phase III clinical trials targeting different types of lung cancer, marking a critical stage in its clinical development [1] - The IMM2510 is developed based on the "mAb-Trap" technology platform and demonstrates antitumor effects through multiple mechanisms [1] Group 2 - Phase I clinical trials showed that IMM2510 achieved an objective response rate (ORR) of 35.3% and a disease control rate of 76.5% in patients with advanced squamous non-small cell lung cancer (sq-NSCLC), with a median progression-free survival (PFS) of 9.4 months and manageable safety [1][2] - Preliminary data from the Phase I clinical study presented at the 2025 World Lung Cancer Conference indicated excellent clinical data and good safety for IMM2510 as a monotherapy in advanced sq-NSCLC patients [2] - Based on positive results, Yiming Oncology plans to further validate the efficacy and safety of IMM2510 in Phase III clinical trials [1]
宜明昂科-B涨超12% IMM2510两项III期注册临床试验已递交EOP2